Literature DB >> 1688373

Transport, metabolism, and effect of chronic feeding of cholylsarcosine, a conjugated bile acid resistant to deconjugation and dehydroxylation.

A Schmassmann1, M A Angellotti, H T Ton-Nu, C D Schteingart, S N Marcus, S S Rossi, A F Hofmann.   

Abstract

To test the effect in rodents of chronic ingestion of a bile acid resistant to deconjugation, cholylsarcosine was synthesized and its transport, metabolism, and effect on biliary bile acid and biliary lipid composition were determined in rabbits, hamsters, and rats. Cholylsarcosine was shown to be well absorbed from the ileum but underwent little absorption from the jejunum or colon. When cholylsarcosine was administered in the diet at 140 mumol/kg.day, it was well absorbed and underwent little biotransformation during enterohepatic cycling; however, both bacterial deconjugation and dehydroxylation (without deconjugation) occurred to a small extent. With chronic feeding, cholylsarcosine accumulated to compose 24%-29% of circulating bile acids in all 3 rodent species. It was rapidly lost from the enterohepatic circulation, with a daily fractional turnover rate of 75%-150%, depending on the species. Cholylsarcosine caused no change in liver tests or hepatic morphology and did not influence biliary lipid secretion. When cholyltaurine was fed, it was also absorbed, but, in contrast to cholylsarcosine, was rapidly deconjugated and dehydroxylated to form deoxycholic acid. The deoxycholic acid accumulated in the enterohepatic circulation, as evidenced by a slow fractional turnover rate of 26%-40% per day, depending on the species. It is concluded that cholylsarcosine is absorbed from the ileum, has an enterohepatic circulation, does not undergo appreciable deconjugation or dehydroxylation in these rodents, and is nontoxic. In the rodent, the circulating bile acids can be somewhat enriched when a bile acid resistant to deconjugation is ingested; but the effect on the steady state biliary bile acid composition is less than that obtained when cholyltaurine is administered because cholyltaurine is biotransformed to deoxycholic acid, which in turn is absorbed and has its own efficient enterohepatic circulation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1688373     DOI: 10.1016/0016-5085(90)91306-q

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  12 in total

1.  Cholylsarcosine for bile acid deficiency caused by ileal resection.

Authors:  O S Popović; N Jojić; D Necić
Journal:  Dig Dis Sci       Date:  1999-09       Impact factor: 3.199

2.  Bile acid absorption after near-total proctocolectomy in dogs: ileal pouch vs. jejunal pouch-distal rectal anastomosis.

Authors:  F V Teixeira; A F Hofmann; L R Hagey; M Pera; K A Kelly
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

Review 3.  Clinical pharmacokinetics of therapeutic bile acids.

Authors:  A Crosignani; K D Setchell; P Invernizzi; A Larghi; C M Rodrigues; M Podda
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

4.  [N-methyl-11C]cholylsarcosine, a novel bile acid tracer for PET/CT of hepatic excretory function: radiosynthesis and proof-of-concept studies in pigs.

Authors:  Kim Frisch; Steen Jakobsen; Michael Sørensen; Ole Lajord Munk; Aage K O Alstrup; Peter Ott; Alan F Hofmann; Susanne Keiding
Journal:  J Nucl Med       Date:  2012-03-27       Impact factor: 10.057

Review 5.  Quantitative PET of liver functions.

Authors:  Susanne Keiding; Michael Sørensen; Kim Frisch; Lars C Gormsen; Ole Lajord Munk
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

6.  Physicochemical and physiological properties of cholylsarcosine. A potential replacement detergent for bile acid deficiency states in the small intestine.

Authors:  J Lillienau; C D Schteingart; A F Hofmann
Journal:  J Clin Invest       Date:  1992-02       Impact factor: 14.808

7.  Effect of replacement therapy with cholylsarcosine on fat malabsorption associated with severe bile acid malabsorption. Studies in dogs with ileal resection.

Authors:  S J Longmire-Cook; J Lillienau; Y S Kim; C D Schteingart; R G Danzinger; O Esch; A F Hofmann
Journal:  Dig Dis Sci       Date:  1992-08       Impact factor: 3.199

8.  Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis.

Authors:  P Ricci; A F Hofmann; L R Hagey; R A Jorgensen; E Rolland Dickson; K D Lindor
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

9.  Design and evaluation of a novel trifluorinated imaging agent for assessment of bile acid transport using fluorine magnetic resonance imaging.

Authors:  Diana Vivian; Kunrong Cheng; Sandeep Khurana; Su Xu; Paul A Dawson; Jean-Pierre Raufman; James E Polli
Journal:  J Pharm Sci       Date:  2014-09-05       Impact factor: 3.534

10.  Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function.

Authors:  P B Jeppesen; P Lund; I B Gottschalck; H B Nielsen; J J Holst; J Mortensen; S S Poulsen; B Quistorff; P B Mortensen
Journal:  Gastroenterol Res Pract       Date:  2009-08-20       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.